A phase II trial of an individualized treatment strategy for patients with metastatic non-clear cell renal carcinoma

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-519070-39-00

Acronym

UR1909

Enrollment

Registered

2024-10-31

Start date

2020-03-06

Completion date

Unknown

Last updated

2024-10-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metastatic non-clear cell renal cell carcinoma

Brief summary

Overall response rate (ORR) + Time-to-treatment failure (TTF)

Detailed description

Progression free survival. Overall survival. Disease control rate. Duration of response. Patient-reported-outcome (PRO) usability. Description of patient-reported-outcome (PRO). Number of hospital admissions. Description of hospital admissions. Description of adverse events.

Interventions

DRUGTafinlar 75 mg hard capsules

DRUGImatinib Accord 400 mg film-coated tablets

DRUGIBRANCE 125 mg hard capsules

DRUGXALKORI 250 mg hard capsules

DRUGYERVOY 5 mg/ml concentrate for solution for infusion

DRUGKadcyla 160 mg powder for concentrate for solution for infusion.

DRUGKEYTRUDA 25 mg/mL concentrate for solution for infusion

DRUGLynparza 100 mg film-coated tablets

DRUGOPDIVO 10 mg/mL concentrate for solution for infusion.

DRUGAlecensa 150 mg hard capsules

DRUGTAGRISSO 80 mg film-coated tablets

DRUGCABOMETYX 60 mg film-coated tablets

DRUGTarceva 150 mg film-coated tablets

DRUGMekinist 2 mg film-coated tablets

DRUGSutent 50 mg hard capsules

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Overall response rate (ORR) + Time-to-treatment failure (TTF)	—

Secondary

Measure	Time frame
Progression free survival. Overall survival. Disease control rate. Duration of response. Patient-reported-outcome (PRO) usability. Description of patient-reported-outcome (PRO). Number of hospital admissions. Description of hospital admissions. Description of adverse events.	—

Countries

Denmark

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026